As the understanding of PCSK9 role in the pathogenesis of hypercholesterolemia evolved, efforts devoted to this unique pathway led to the development of monoclonal antibodies against PCSK9 [188]. This evidence concerns the gene PCSK9 and Hypercholesterolemia.